Asya Nina Varshavsky Yanovsky, MD
Hematology & Oncology · Philadelphia, PANPI 1093147118
Payments from drug & device makers
Across 190 payments — averaging $11,621 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$1.1M
- Pfizer$838K
- E.r. Squibb & Sons, L.L.C.$92K
- Otsuka Pharmaceutical Co., Ltd.$70K
- Janssen Research & Development, LLC$41K
- AbbVie$37K
- plus $74K from 15 others
Across 9 payments — averaging $633.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$6K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 10 | $1,055,854 |
| Pfizer | 96 | $838,199 |
| E.r. Squibb & Sons, L.L.C. | 8 | $91,523 |
| Otsuka Pharmaceutical Co., Ltd. | 17 | $70,104 |
| Janssen Research & Development, LLC | 9 | $41,170 |
| AbbVie | 8 | $36,755 |
| GSK | 7 | $35,765 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $28,982 |
| Johnson & Johnson | 7 | $3,945 |
| Janssen Scientific Affairs, LLC | 4 | $3,898 |
| Taiho Oncology, Inc. | 1 | $1,325 |
| Daiichi Sankyo Inc. | 4 | $90 |
| Amgen | 2 | $87 |
| Novartis | 2 | $84 |
| AstraZeneca | 3 | $62 |
| Astellas Pharma US Inc | 1 | $30 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $30 |
| Pharmaessentia USA Corporation | 1 | $23 |
| Legend Biotech USA Inc. | 1 | $18 |
| Incyte Corporation | 1 | $18 |
| Morphosys, US Inc. | 1 | $15 |
How this compares
$2,207,976 in reported general payments places this provider in the 95th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Philadelphia
- Stephen BagleyPhiladelphia$13.1M
- Stephen SchusterPhiladelphia$9.5M
- Pooja GhataliaPhiladelphia$8.3M
- Corey LangerPhiladelphia$7.7M
- Alfred GarfallPhiladelphia$7.6M
- Charu AggarwalPhiladelphia$7M
- Marcela MausPhiladelphia$4.4M
- Catherine LaiPhiladelphia$3.8M
- James StevensonPhiladelphia$3.4M
- Tara MitchellPhiladelphia$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.